Am­gen, No­var­tis cel­e­brate promis­ing mi­graine da­ta, but Te­va and Alder are prepar­ing to crash the par­ty

Am­gen $AMGN post­ed some im­pres­sive re­sults for its Phase II study of a close­ly-watched mi­graine drug, but the big biotech may still be forced to ac­cept a shrink­ing share of what is shap­ing up as a high­ly com­pet­i­tive mar­ket as ri­vals crowd the same sec­tor.

The key da­ta on erenum­ab: 40 per­cent and 41 per­cent of the pa­tients in the two dose arms (70 mg and 140 mg dos­es) ex­pe­ri­enced a re­duc­tion of 50% or more in the num­ber of mi­graine days record­ed at week 12, com­pared to about one in 4 (24%) of those tak­ing a place­bo.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER